There were 13 males (59.1%) in the LRRK2+ PD group, 14 males (58.33%) in the LRRK2− PD group, 24 males (63.16%) in the LRRK2+ control group and 14 males (8.33%) in the LRRK2− control group. The gene discussed is LRRK2; the disease is Parkinson disease.